Allo-SCT using BU, CY and melphalan for children with AML in second CR.

Item

http://www.wikidata.org/entity/Q53108503

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@en

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@nl

type

Item

label

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@en

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@nl

prefLabel

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@en

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@nl

P1476

Allo-SCT using BU, CY and melphalan for children with AML in second CR.

@en

P2093

A Borkhardt

http://www.w3.org/2001/XMLSchema#string

A Schrauder

http://www.w3.org/2001/XMLSchema#string

A Schulz

http://www.w3.org/2001/XMLSchema#string

B Gruhn

http://www.w3.org/2001/XMLSchema#string

B Kremens

http://www.w3.org/2001/XMLSchema#string

B Strahm

http://www.w3.org/2001/XMLSchema#string

C Mauz-Körholz

http://www.w3.org/2001/XMLSchema#string

C Peters

http://www.w3.org/2001/XMLSchema#string

D Reinhardt

http://www.w3.org/2001/XMLSchema#string

F R Schuster

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.

Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.

High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors.

High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.

P2888

bmt.2012.204

P304

651-656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2012.204

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ingo Müller

P577

2012-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232720166

http://www.w3.org/2001/XMLSchema#string

P698

23103678

http://www.w3.org/2001/XMLSchema#string